| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2014 | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study | Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO ; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S. | The Lancet | 300 | 276 | |
| 2017 | Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1 | JIA-HORNG KAO ; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. | Journal of Gastroenterology and Hepatology (Australia) | 16 | 12 |
